Another company (private) developing an FXR agonist for NASH: https://www.prnewswire.com/news-releases/metacrine-completes-series-b-financing-to-advance-best-in-class-fxr-program-into-clinical-development-300568144.html https://endpts.com/rich-heymans-metacrine-grabs-a-22m-round-in-search-of-a-superior-nash-drug